Research and Markets has announced the addition of the "Global Autoimmune Partnering 2010-2016: Deal trends, players and financials" report to their offering.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
Global Autoimmune Partnering 2010 to 2016 provides
The report includes coverage of the following autoimmune diseases:
The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Autoimmune dealmaking
Chapter 3 - Financial deal terms for Autoimmune partnering
Chapter 4 - Leading Autoimmune deals and dealmakers
Chapter 5 - Autoimmune contract document directory
Chapter 6 - Autoimmune dealmaking by therapeutic target
For more information about this report visit http://www.researchandmarkets.com/research/xjp544/global_autoimmune
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006005832/en/Business Wire
Last updated on: 06/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.